

Spectrophotometric assays

Objectives:

Spectrophotometric assays allows the determination of the concentration of a substance of interest in various biological samples (urine, blood, plasma, tissue) and helps to better understand the mechanism of action of an active compound.

Summarized methodology:

A wide range of assays have been validated based on direct colorimetric reactions or immuno-enzymatic detection (EIA / ELISA).

Pelvipharm is used to collect various sample types (urine, blood, plasma, tissue), while taking special care to adopt an appropriate storage of samples and to perform pre-analytical steps (extraction when needed) before any biochemical spectrophotometric assay.

Absorbance reading is performed using a Molecular Devices microplate reader (Spectramax 190) associated to SoftMax® Pro microplate analysis software.

Endpoints:

A wide range of biochemical spectrophotometric assays have been validated at Pelvipharm, as follows:

Type of marker	Assays validated at Pelvipharm
Inflammation	TNF α IL-6
Nerve growth	NGF
Renal function	creatinine albumin
Metabolism	glycemia insulin triglycerides
Endothelial function	6-keto-prostaglandin F1 α thromboxane A2 cyclic GMP endothelin nitrites/nitrates
Oxidative stress	8-isoprostanes antioxidant capacity
Remodeling	protein content DNA content hydroxyproline

NB: Pelvipharm will gladly study the feasibility of performing additional spectrophotometric assays to meet its client's needs.

Related Pelvipharm bibliography:

Oudot, A. et al. **J Sex Med** (2010) : 7(1)p1:79-88
 Oudot, A. et al. **Physiol Res** (2009) : 58(4):499-509.
 Behr-Roussel, D. et al. **Am J Hypertens** (2008) : 21(11) : 1258-1263
 Behr-Roussel, D. et al. **Eur Urol** (2008) : 53(6) : 1272-1280
 Behr-Roussel, D. et al. **Am J Physiol – Regul** (2005) : 288 : R276-R283
 Behr-Roussel, D. et al. **Atherosclerosis** (2002) : 162 : 355-362

Links to applicable therapeutic areas / targeted disorders:

- Sexual pharmacology

- * ED (Erectile Dysfunction)
- * Ejaculatory Disorders
- * FSD (Female Sexual Dysfunction)

- Lower urinary tract

- * BPH (Benign prostatic Hyperplasia)
- * SUI (Stress Urinary Incontinence)
- * SCI (Spinal Cord Injury)
- * NDO (Neurogenic Detrusor Overactivity)
- * OAB (Overactive Bladder)
- * IC (Interstitial Cystitis)

- Cardiovascular and metabolism pharmacology

- * Hypertension
- * Metabolic syndrome
- * Atherosclerosis
- * Diabetes Mellitus
- * Myocardial infarction